PANS
6
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Biomarkers for Diagnosis and Treatment Response in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Characterization and Prospective Course
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS